MedElevator Войти в исследования
← Поиск публикаций

DOI 10.7759/cureus.23627

Медицинская библиотека · Cureus · 2022

Partial Response to Small Molecule Inhibition in a Case of Anaplastic Large Cell Lymphoma.

Young Sarah, Kuzu Amirah, Magill Mike, Hajdenberg Julio

Клинический случайСтатьяПеревод пока не подготовлен

Аннотация

In the era of personalized medicine, small-molecule inhibitors have become key to targeting many malignancies. Multiple hematologic malignancies are driven by small-molecule pathways that are seemingly ripe for such targeting. In this case report, we present a patient who was treated with a mitogen-activated extracellular signal-regulated kinase (MEK) inhibitor for what was originally diagnosed as a histiocytic sarcoma. Re-biopsy ultimately revealed an anaplastic lymphoma kinase (ALK)-negative anaplastic large cell lymphoma (ALCL), but his disease initially showed a remarkable response to MEK inhibition. This case illustrates both the importance of obtaining high-quality biopsy specimens for diagnostic and molecular analysis as well as the need for further research into the molecular drivers of T-cell lymphomas that may be amenable to targeted therapies.

Для цитирования: Young Sarah, Kuzu Amirah, Magill Mike, Hajdenberg Julio. Partial Response to Small Molecule Inhibition in a Case of Anaplastic Large Cell Lymphoma.. Cureus. 2022. DOI: 10.7759/cureus.23627.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.